Drug Innovation in Ageing

Population ageing is a phenomenon of the 21st Century, and its consequences - both positive and not so positive – are being experienced globally. Many nations are being challenged by not only an increase in the number of older people but also different expectations of younger generations. Chronic illness has surpassed infectious diseases as the main cause of death, and the largest cohort of our global population are at higher risk of suffering from such a condition.

Medical research and drug innovation, it could be said, aim to support the independence of older people, to remain healthy and active in their community as long as possible. With technological advances and systems applications, drug innovation has the capacity to influence and to some extent, enhance the functional capacity and improve the quality of life for older adults.

Given the demographic trend and its consequences, progress in medicine and chronic disease management will take on a more significant role to alleviate increased demands in care and improve quality of life for older adults.

The organizing committee is interested in receiving abstracts that speak to the impact of drug innovation practices and its impact on the older population segment. Furthermore, session abstracts that demonstrate the cost benefit analysis of drug innovation on the economy and social society in general are of particular interest.